



Sign up for the [PharmacyTimes Newsletter](#)

SHOWING CONTENT FOR: [Community Pharmacist](#)

[Login](#)

[Clinical Resources](#)

[Videos](#)

[Publications](#)

[Contributors](#)

[Conference Coverage](#)

[Continuing Education](#)

Search



[Back to issue](#)

Apotex Corp. A Global Leader Focused on Excellence

JULY 11, 2014



Apotex Corp., headquartered in Weston, Florida, is the US subsidiary of Apotex Inc., the largest Canadian-owned pharmaceutical company. Apotex Inc. produces more than 780 generic pharmaceutical products in approximately 2300 SKUs and exports to 121 countries globally. The company has successfully secured FDA approval for over 250 ANDAs—with another 375 currently in active development.

Apotex Corp. is frequently recognized for outstanding service by customers and is ranked in the top 10 generic pharmaceutical manufacturers according to recent IMS Health data. Apotex's expansive product portfolio spans a wide range of dosage forms and therapeutic classes, including cardiovascular, anti-infectives, gastrointestinal, central nervous system, mental health, pain management, and respiratory. The company continues to diversify its product mix by adding new therapeutic areas and dosage forms such as transdermal patches and injectables. Earlier this year, Apotex launched several new products, including 2 first-to-market generics—Budesonide Nasal Spray (generic equivalent to Rhinocort Aqua®) and Diclofenac Topical Solution (generic equivalent to Pennsaid®). With a number of first-to-file submissions and first-to-file market launches in our pipeline, Apotex is well positioned for growth.

Commitment to Quality and Global Supply Chain Efficiencies

Apotex's highest priority is its Global Quality Program, which it considers integral to maintaining its strategic industry relationships. Over the past 4 years, Apotex has invested up to \$150 million in new quality systems, technologies, and new software solutions. "Quality is something that we can never say we've done—it's a continuous journey," says Jeremy Desai, president and COO of Apotex Inc. "We have the advantage of being vertically integrated, and a large percentage of products we develop, we manufacture the pharmaceutical ingredient—the API," says Desai.

Investing for Tomorrow

New generic products are a critical component of Apotex's growth. Apotex has historically reinvested close to 20% of its revenues in research and development. More importantly, Apotex is focused on more than simply developing new generics; the company is also working actively to develop a broad portfolio of biosimilars.

According to Desai, "Apotex is being built on a vision that is to provide affordable health care to patients across the globe." Deeply entrenched in the company's culture is the ability to adapt quickly by staying relevant in the changing health care industry landscape.

Reliable Advocate and Trusted Partner

Among generic manufacturers, Apotex stands alone in opposing anticompetitive patent settlements that delay generic competition, both by litigating against them and in advocating against them to the Federal Trade Commission and to Congress.

Apotex believes that all manufacturers have a corporate citizenship responsibility to the global community. The company performs this responsibility through various national initiatives and partnerships. Apotex provides educational support to pharmacy students through a partnership with



To help patients get off to a good start

DISCOVER THE BEGINSULIN EXPERIENCE

[Full Prescribing Information](#)

INDICATION AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

WARNINGS AND PRECAUTIONS

BASAGLAR KwikPen® must never be shared between patients.

The Power of One: How Partnering Can Enhance Your Independent Brand

The Mom and Pops and stand-alones out there need to come together and form an alliance.



To help patients get off to a good start

DISCOVER THE BEGINSULIN EXPERIENCE

[Full Prescribing Information](#)

INDICATION AND IMPORTANT SAFETY INFORMATION

ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

WARNINGS AND PRECAUTIONS



CLICK HERE

for partner access to continuing education.

Pharmacist Education

Clinical features with downloadable PDFs

lifesaving medicines to developing countries to alleviate human suffering and save the lives of thousands of people. Apotex is committed to serving the global community by providing the highest quality of affordable generic medicines.

For more information, visit www.apotexcorp.com.

SHARE THIS



RELATED COVERAGE



Clinical Use of Generic Injectable Drugs in Hospitalized Patients

Generic Product News (September 2017)

Generic Product News (August 2017)

YOU MAY ALSO BE INTERESTED IN



Clinical Use of Generic Injectable Drugs in Hospitalized Patients



Generic Product News (September 2017)



Generic Product News (August 2017)

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER

Personalize the information you receive by selecting targeted content and special offers.

Enter your email address

Sign Up



RELATED SITES



About Pharmacy Times

Pharmacy Times® is the #1 full-service pharmacy media resource in the industry. Founded in 1897, Pharmacy Times® reaches a network of over 1.3 million retail pharmacists. Through our print, digital and live events channels, Pharmacy Times® provides clinically based, practical and timely information for the practicing pharmacist. Features and specialized departments cover medication errors, drug interactions, patient education, pharmacy technology, disease state management, patient counseling, product news, pharmacy law and health-system pharmacy. Pharmacy Times Continuing Education™ (PTCE) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.



Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-9038

Copyright © 2006-2017 Pharmacy & Healthcare Communications, LLC. All Rights Reserved.

